This study aims to determine serum galectin-3 levels in COPD patients in stable and exacerbation periods, to determine the possible relationship between galectin-3 and various biomarkers, and to analyze the power of galectin-3 in predicting exacerbations. Here, LGALS3 is linked to chronic obstructive pulmonary disease.